Thermo Fisher Scientific Inc. (NYSE:TMO) Position Lifted by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Thermo Fisher Scientific Inc. by 4.1% during the first quarter, owning 2,925,591 shares worth approximately $1.46 billion as of the latest filing.
• Thermo Fisher Scientific reported $5.36 EPS for the last quarter, exceeding analysts' expectations of $5.22, with revenues of $10.86 billion, up 2.9% year-over-year.
• The company recently declared a quarterly dividend of $0.43 per share, indicating an annual yield of 0.4% and a payout ratio of 9.95%.

Charles Schwab Investment Management Inc. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,925,591 shares of the medical research company's stock after purchasing an additional 115,463 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.78% of Thermo Fisher Scientific worth $1,455,774,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after purchasing an additional 230,382 shares during the last quarter. Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 1.1% during the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after purchasing an additional 104,343 shares during the period. Northern Trust Corp grew its position in Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after buying an additional 455,004 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after buying an additional 1,433,444 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in shares of Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after acquiring an additional 193,378 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 8,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $454.45, for a total value of $3,635,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,340,824.30. The trade was a 6.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,400 shares of company stock worth $8,345,792 in the last quarter. Insiders own 0.33% of the company's stock.

Analyst Ratings Changes

TMO has been the topic of a number of analyst reports. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research note on Friday, July 11th. Stifel Nicolaus dropped their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Argus decreased their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Finally, Raymond James Financial restated an "outperform" rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Six analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Trading Up 1.5%

TMO stock traded up $6.60 during midday trading on Friday, reaching $461.34. 1,689,914 shares of the company's stock traded hands, compared to its average volume of 3,227,669. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The business has a 50-day moving average price of $426.80 and a two-hundred day moving average price of $464.17. The company has a market capitalization of $174.21 billion, a P/E ratio of 26.68, a PEG ratio of 2.43 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period in the prior year, the company earned $5.37 EPS. The firm's revenue was up 2.9% on a year-over-year basis. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.